What is Ukko?
Ukko operates as a pioneering AI-driven biotechnology company dedicated to solving the complex challenges of food sensitivities and allergies. By utilizing a sophisticated computational platform, the firm identifies and modifies proteins that trigger adverse immune responses, effectively redesigning food ingredients to be safer without compromising taste or nutritional value. This market position is critical as global demand for personalized nutrition and allergen-friendly food products continues to accelerate. Ukko's unique methodology allows for rapid prototyping and validation, providing a scalable solution to a pervasive health issue that affects millions of consumers worldwide.
How much funding has Ukko raised?
Ukko has raised a total of $47.7M across 2 funding rounds:
Series A
$7.7M
Series B
$40M
Series A (2017): $7.7M with participation from Slow Ventures, Izhar Armony, Marc Benioff, Innovation Endeavors, and Khosla Ventures
Series B (2021): $40M led by Continental Grain Company, Fall Line Capital, Leaps by Bayer, Peak Bridge Ventures, and Skyviews Life Science
Key Investors in Ukko
Continental Grain Company
CGC is a global investor, owner, and operator of companies across the food, agribusiness, and commodities spectrum. The company was founded in 1813 and is headquartered in New York City.
Fall Line Capital
Fall Line Capital specializes in redefining investment in farmland and technology across the United States, focusing on enhancing agricultural productivity through innovative tech.
Khosla Ventures
A prominent venture capital firm that provides strategic support and capital to early-stage and growth-stage companies, with a strong focus on transformative technology and science-based ventures.
What's next for Ukko?
With the recent infusion of capital, Ukko is well-positioned to transition from its research-heavy development phase into broader commercialization and strategic partnerships. The company is expected to focus on expanding its pipeline of hypoallergenic ingredients and deepening its integration with major food manufacturers. As the firm scales, the focus will likely shift toward regulatory milestones and the deployment of its technology across diverse food categories. By maintaining its commitment to data-driven protein engineering, Ukko aims to set a new standard for safety and quality in the global food supply chain, ultimately transforming how the industry approaches food sensitivity management.
See full Ukko company page
